AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37041057
Drug: Oral immunonutritional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immunonutritional supplement (INS)
Trial: 37041081
Drug: Renal replacement
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renal replacement therapy during ICU stay
Trial: 37041205
Drug: D-Cycloserine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-Cycloserine (100 mg) with repeated spaced iTBS
Trial: 37041472
Drug: BPI-9016M 300
RxNorm normalized name: BPI-3016
DrugBank: BPI-3016 (DB15158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPI-9016M 300 mg QD
Trial: 37041472
Drug: BPI-9016M 450
RxNorm normalized name: BPI-3016
DrugBank: BPI-3016 (DB15158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPI-9016M 450 mg QD
Trial: 37041472
Drug: BPI-9016M 600
RxNorm normalized name: BPI-3016
DrugBank: BPI-3016 (DB15158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPI-9016M 600 mg QD
Trial: 37041472
Drug: BPI-9016M 400
RxNorm normalized name: BPI-3016
DrugBank: BPI-3016 (DB15158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPI-9016M 400 mg BID (Part B)
Trial: 37041539
Drug: Filapixant 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filapixant 80 mg
Trial: 37041539
Drug: Filapixant 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filapixant 250 mg
Trial: 37041967
Drug: Other SARS-CoV-2
RxNorm normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other SARS-CoV-2 directed treatment
Trial: 37042037
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dabrafenib (150 mg twice daily), trametinib (2 mg once daily), and AT13387 (260 mg/m)
Trial: 37042037
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dabrafenib, trametinib, and AT13387
Trial: 37042724
Drug: Chemotherapy (ADjuVANt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (ADjuVANt Chemotherapy in the Elderly trial)
Trial: 37042921
Drug: Alemtuzumab levels
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alemtuzumab levels ≤0.32 μg/mL
Trial: 37042921
Drug: Alemtuzumab levels
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alemtuzumab levels >0.32 μg/mL
Trial: 37042921
Drug: Day 0
RxNorm normalized name: Apri 28-Day 0.03mg-0.15mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 0 alemtuzumab levels >0.32 μg/mL
Trial: 37042921
Drug: CXCL9 levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CXCL9 levels ≤2394 pg/mL (day 14+ median)
Trial: 37042921
Drug: CXCL9 levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CXCL9 levels >2394 pg/mL (day 14+)
Trial: 37043021
Drug: Robot-assisted cochlear
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-assisted cochlear implant surgery (RACIS)
Trial: 37043201
Drug: Intrapleural tissue
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapleural tissue plasminogen activator plus deoxyribonuclease therapy
Trial: 37043203
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as Usual (TAU) with methadone
Trial: 37043210
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy alone (recurrence score <11)
Trial: 37043210
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy alone vs chemotherapy followed by endocrine therapy (recurrence score 11-25)
Trial: 37043210
Drug: Chemotherapy followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy followed by endocrine therapy (recurrence score >25)
Trial: 37043339
Drug: 1% atropine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% atropine weekly for 6 months
Trial: 37043339
Drug: 0.01% atropine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01% atropine daily for 6 months (phase 2)
Trial: 37043339
Drug: 0.01% atropine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01% atropine daily for 1 year (group B)
Trial: 37043386
Drug: Baseline high-sensitivity
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline high-sensitivity troponin T (hsTnT) ≥14 ng/L
Trial: 37043386
Drug: 6-predictor model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-predictor model including age, sex, eGFR <45 mL·min -1 ·1.73 m -2, functional capacity <4 METs or unknown, NT-proBNP ≥300 pg/mL, and estimated intraoperative blood loss
Trial: 37043520
Drug: 20 mmol
RxNorm normalized name: dibasic potassium phosphate 120 MMOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mmol KCl intravenous injection
Trial: 37043518
Drug: Congenital combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Congenital combined pituitary hormone deficiency (cCPHD) diagnosed before age 18 years
Trial: 37043518
Drug: Congenital combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Congenital combined pituitary hormone deficiency (cCPHD) diagnosed <1 year
Trial: 37043518
Drug: Congenital combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Congenital combined pituitary hormone deficiency (cCPHD) diagnosed 1-17 years
Trial: 37043518
Drug: Congenital combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Congenital combined pituitary hormone deficiency (cCPHD)
Trial: 37043653
Drug: Dersimelagon 100
RxNorm normalized name: Dersimelagon
DrugBank: Dersimelagon (DB18007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dersimelagon 100 mg once daily for 16 weeks
Trial: 37043653
Drug: Dersimelagon 300
RxNorm normalized name: Dersimelagon
DrugBank: Dersimelagon (DB18007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dersimelagon 300 mg once daily for 16 weeks
Trial: 37044281
Drug: Oral NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral NaCl (2 grams 3 times a day)
Trial: 37044281
Drug: Oral NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral NaCl
Trial: 37044364
Drug: Multifaceted strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifaceted strategy with a multidisciplinary approach including telehealth tools, continued education, pharmacological and non-pharmacological treatment, and behavioral change.
Trial: 37045500
Drug: Abbreviated antiplatelet
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abbreviated antiplatelet therapy (APT)
Trial: 37045500
Drug: Standard antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antiplatelet therapy (APT)
Trial: 37045504
Drug: CYP2C19 genotyping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP2C19 genotyping with clopidogrel-based therapy (RMs or NMs)
Trial: 37045504
Drug: CYP2C19 genotyping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP2C19 genotyping with clopidogrel-based therapy (IMs or PMs)
Trial: 37045565
Drug: Dopamine or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine or Epinephrine administration
Trial: 37045569
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid (1.6%) + chondroitin sulfate (2%) therapy (Ialuril)
Trial: 37045708
Drug: Low-dose naltrexone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose naltrexone (LDN) 4.5 mg for 8 weeks
Trial: 37046094
Drug: Antibodies against
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibodies against endogenous retroviruses
Trial: 37046122
Drug: 8 g
RxNorm normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 g per day I + AX for 21 days
Trial: 37046290
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behavioral therapy (CBT) for tinnitus
Trial: 37046681
Drug: Fluvastatin (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin (6 mg/kg/day) with Celecoxib (fixed daily dose)
Trial: 37048135
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of copeptin and hs-cTnT
Trial: 37049576
Drug: Food supplement
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food supplement (probiotics, prebiotics, vitamin D, zinc, and selenium)
Trial: 37050861
Drug: Venglustat administered
RxNorm normalized name: Venglustat
DrugBank: Venglustat (DB14966)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venglustat administered as food admixture
Trial: 37050937
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Global Registry of Acute Coronary Events (GRACE) score with ceramides
Trial: 37051014
Drug: Participants' estimates
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants' estimates of others' cannabis use (weekly or more often)
Trial: 37051129
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition (PN) from postoperative day 1 to day 5 plus oral food 'at will' (treatment arm)
Trial: 37051129
Drug: Oral food
RxNorm normalized name: Nutritional Supplement Oral Food, Solid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral food 'at will' alone (control arm)
Trial: 37051756
Drug: Venetoclax 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax 600 mg daily with azacitidine during induction cycles; maintenance arms included azacitidine with 400 mg venetoclax or 400 mg venetoclax alone.
Trial: 37051756
Drug: MRD guidance
RxNorm normalized name: ZINC OXIDE 120 mg in 1 mL TOPICAL CREAM [GUIDANCE TO GLOW TRU SPF 35]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRD guidance for azacitidine discontinuation
Trial: 37051756
Drug: Venetoclax doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax doses >400 mg with azacitidine
Trial: 37051821
Drug: Glenohumeral joint
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glenohumeral joint corticosteroid injection
Trial: 37053246
Drug: Sequential bilateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential bilateral accelerated theta burst stimulation (aTBS) administered as 3 sessions daily for 10 days, with 1,800 pulses delivered continuously to the right DLPFC and intermittently to the left DLPFC.
Trial: 37053246
Drug: Sham TBS
RxNorm normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham TBS treatment administered as 3 sessions daily for 10 days.
Trial: 38758212
Drug: Automated Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Automated Insulin Delivery
Trial: 37053529
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard insulin delivery)
Trial: 37054503
Drug: Tyrosine receptor
RxNorm normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tyrosine receptor kinase inhibitor (TRKi) treatment in patients with simple genomics NMT.
Trial: 37054503
Drug: First-generation TRKi
RxNorm normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-generation TRKi treatment in patients with complex genomics NMT.
Trial: 37054556
Drug: Gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine plus platinum chemotherapy (GC) + bevacizumab
Trial: 37054556
Drug: Gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine plus platinum chemotherapy (GC)
Trial: 37054888
Drug: β-glucan 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-glucan 1.5 g
Trial: 37054888
Drug: β-glucan 3
RxNorm normalized name: Beta glucan
DrugBank: Yeast beta-D-glucan (DB19271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-glucan 3 g
Trial: 37054888
Drug: β-glucan 6
RxNorm normalized name: Beta glucan
DrugBank: Yeast beta-D-glucan (DB19271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-glucan 6 g
Trial: 37055198
Drug: 6 L NC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 L NC 100% oxygen
Trial: 37055205
Drug: SIESTA in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIESTA in combination with treatment as usual (TAU) for ADHD
Trial: 37055207
Drug: SOC+L (Leflunomide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC+L (Leflunomide 100 mg/day for 3 days followed by 10-20 mg/day for 7 days)
Trial: 37055207
Drug: SOC+L
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC+L
Trial: 37055279
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with 6 cycles of gemcitabine
Trial: 37055279
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with 3 cycles of gemcitabine followed by chemoradiation therapy (CRT) and another 3 cycles of gemcitabine
Trial: 37055640
Drug: Circulating tumour
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Circulating tumour DNA (ctDNA) detection and profiling after curative intent therapy
Trial: 37055702
Drug: Air-Q Blocker
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air-Q Blocker
Trial: 37056765
Drug: Radiotherapy of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy of 24 Gy/3 fractions/3-10 days plus liposomal irinotecan (80mg/m) followed by camrelizumab and anti-angiogenic treatment
Trial: 37057394
Drug: Anti-TG2 antibodies
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-TG2 antibodies
Trial: 37058479
Drug: Vaccination (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination (2 doses)
Trial: 37058726
Drug: Any opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any opioid administration
Trial: 37058726
Drug: Lowest opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowest opioid dose group
Trial: 37058726
Drug: Third opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third opioid dose group
Trial: 37059327
Drug: S201086/GLPG1972 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S201086/GLPG1972 75 mg
Trial: 37059327
Drug: S201086/GLPG1972 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S201086/GLPG1972 150 mg
Trial: 37059327
Drug: S201086/GLPG1972 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S201086/GLPG1972 300 mg
Trial: 37060053
Drug: Pragmatic digital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pragmatic digital health obesity treatment intervention
Trial: 37060055
Drug: AGuIX nanoparticles
RxNorm normalized name: Doxorubicin nanoparticles
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AGuIX nanoparticles (50, 75, and 100 mg/kg) added to standard concomitant radio-chemotherapy (temozolomide and radiotherapy)
Trial: 37060236
Drug: Fixed Starting
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed Starting Dose (FSD) of niraparib, 300 mg once daily
Trial: 37060236
Drug: Individualized Starting
RxNorm normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Individualized Starting Dose (ISD) of niraparib, 200 mg once daily for patients with baseline body weight < 77 kg or baseline platelet count < 150,000/µL; 300 mg once daily for all other patients
Trial: 37060236
Drug: Individualized Starting
RxNorm normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Individualized Starting Dose (ISD) of niraparib
Trial: 37060236
Drug: Fixed Starting
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed Starting Dose (FSD) of niraparib
Trial: 37060420
Drug: Photobiomodulation (PBM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation (PBM) therapy - three sessions each week for 12 weeks
Trial: 37060432
Drug: Relugolix in
RxNorm normalized name: Product containing relugolix in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relugolix in combination with abiraterone
Trial: 37060432
Drug: Relugolix in
RxNorm normalized name: Product containing relugolix in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relugolix in combination with apalutamide
Trial: 37060458
Drug: Dersimelagon (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dersimelagon (oral selective MC1R agonist)
Trial: 37060545
Drug: High-dose VE303
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose VE303 (8.0 × 10^9 CFUs)
Trial: 37060545
Drug: Low-dose VE303
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose VE303 (1.6 × 10^9 CFUs)
Trial: 37060917
Drug: ChAdOx1 RVF
RxNorm normalized name: ChAdOx1 nCoV-19
DrugBank: AstraZeneca COVID-19 Vaccine (DB15656)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAdOx1 RVF vaccine (5 × 10^10 viral particles)
Trial: 37061109
Drug: Cenicriviroc (CVC)
RxNorm normalized name: salicylic acid
DrugBank: Cenicriviroc (DB11758)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenicriviroc (CVC) 150 mg once daily for 12 months
Trial: 37061169
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CADe (GI-Genius; Medtronic) and Endocuff Vision (ECV; Olympus)
Trial: 37061234
Drug: ETN monotherapy
RxNorm normalized name: ETN
DrugBank: Erythrityl tetranitrate (DB01613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ETN monotherapy
Trial: 37060915
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose corticosteroids (dexamethasone 20 mg once daily for 5 days followed by 10 mg once daily for 5 days)
Trial: 37060915
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (including low-dose corticosteroids 6 mg once daily for 10 days)
Trial: 37060915
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose corticosteroids
Trial: 37061361
Drug: Supervised high-intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised high-intensity interval training during neoadjuvant chemoradiation therapy
Trial: 37061361
Drug: Unsupervised moderate-to-vigorous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unsupervised moderate-to-vigorous exercise after therapy
Trial: 37061619
Drug: Atezolizumab (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (1200 mg IV, Q3weeks × 4) and nab-paclitaxel (100 mg/m2)
Trial: 37061715
Drug: Comprehensive supervised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive supervised exercise program (CSEP) consisting of a 12-week intensive phase with 3 exercise sessions of 1 hour per week, followed by a maintenance phase with home exercises and monthly tele-consultations with a physiotherapist.
Trial: 37061794
Drug: $500 monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: $500 monthly stipend
Trial: 37061810
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 10 or 30 µg daily
Trial: 37062298
Drug: Ritlecitinib 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritlecitinib 200 mg + 50 mg
Trial: 37062298
Drug: Ritlecitinib 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritlecitinib 200 mg + 30 mg
Trial: 39445776
Drug: Ritlecitinib 50
RxNorm normalized name: ritlecitinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritlecitinib 50 mg
Trial: 37062422
Drug: TG103 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TG103 3 mg
Trial: 37062422
Drug: TG103 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TG103 7.5 mg
Trial: 37062422
Drug: TG103 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TG103 15 mg
Trial: 37062422
Drug: TG103 22.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TG103 22.5 mg
Trial: 37062500
Drug: First-line anti-TNF
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line anti-TNF therapy
Trial: 37062579
Drug: Caregiver's gender,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caregiver's gender, biological relatedness, household composition, and family cohesion
Trial: 37062658
Drug: Dual immuno-oncology
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual immuno-oncology agents (IO+IO)